Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2004

View Archived Issues

Oral consumption of green tea polyphenols curbs prostate cancer progression in vivo

5-HT2A/2C agonist improves upper airway stability in rats

Parkin gene therapy shows promise for treatment of PD

Merck & Co.: pipeline review

Three recent Merck patents cover metabotropic glutamate receptor modulators

Novel tyrosine kinase inhibitors claimed by IRM

Astex describes novel MAP kinase inhibitors and their use in inflammatory conditions

New PARP inhibitors emerge from Inotek R&D

Memorial Sloan-Kettering and Columbia U. collaboration yields novel HDAC inhibitors for cancer

New analgesic agents prepared and tested at LSU

Long-term safety of bicifadine evaluated in new phase III trial

Milestone in Merck's PER.C6-related HIV program

Diamyd to be tested in type 1 diabetes

HuMax-CD20 receives fast track designation in CLL

Cell Therapeutics enters licensing agreements for bisplatinum compounds

Wyeth seeks global approval of Tygacil

Nasonex approved in U.S. for nasal polyps

Johnson & Johnson to acquire Guidant

Serono and CancerVax form global collaboration for Canvaxin

DTS-201 set to enter clinical trials in Europe

TAP submits febuxostat NDA for management of hyperuricemia in gout

Oblimersen not active in patients with multiple myeloma, but benefits patients with CLL

New data on the activity of tipifarnib in acute myeloid leukemia

Preclinical, clinical results for CC-5013 in multiple myeloma and myelodysplastic syndromes reported

Eligard six-month depot receives FDA approval

rEV-131 for postcataract surgery impresses in preclinical study

Pfizer submits Revatio for pulmonary arterial hypertension

Eisai receives positive opinion for Zonegran in Europe

FDA approval for Kepivance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...